Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

1356803

USP

Lactulose

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

4-O-β-D-Galactopyranosyl-D-fructofuranose, 4-O-β-D-Galactopyranosyl-D-fructose

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C12H22O11
CAS Number:
4618-18-2
Molecular Weight:
342.30
Beilstein:
93773
MDL number:
MFCD00151469
UNSPSC Code:
41116107
PubChem Substance ID:
329750229
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

lactulose

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@@](O)(CO)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O

InChI

1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12+/m1/s1

InChI key

JCQLYHFGKNRPGE-WJONTELPSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lactulose USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Lactulose Concentrate
  • Lactulose Solution

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 4

1 of 4

Anhydrous lactose United States Pharmacopeia (USP) Reference Standard

USP

1356676

Anhydrous lactose

USP

USP

1287700

Galactose

Fructose United States Pharmacopeia (USP) Reference Standard

USP

1286504

Fructose

Lactose, Anhydrous Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1025

Lactose, Anhydrous

J Zhao et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 26(6), 794-802 (2014-03-20)
Small intestinal bacterial overgrowth (SIBO) may be a cause of irritable bowel syndrome (IBS); however, current investigations have important limitations. We aimed to identify clinically relevant diagnostic criteria for SIBO based on lactulose hydrogen breath test (LHBT) alone and combined
Kostan W Reisinger et al.
Journal of pediatric gastroenterology and nutrition, 59(6), 720-724 (2014-08-12)
The incidence of necrotizing enterocolitis (NEC) is higher in formula-fed babies than in breast-fed babies, which may be caused by breast-feeding-induced gut maturation. The effect of breast-feeding on gut maturation has been widely studied in animal models. This study aimed
Jun Fang et al.
Journal of pharmaceutical sciences, 103(10), 3235-3243 (2014-07-22)
Bacteria of micrometer size could accumulate in tumor based on enhanced permeability and retention (EPR) effect. We report here Lactobacillus casei (L. casei), a nonpathogenic facultatively anaerobic bacterium, preferentially accumulated in tumor tissues after intravenously (i.v.) injection; at 24 h
T V Kot et al.
The Annals of pharmacotherapy, 26(10), 1277-1282 (1992-10-01)
To review the current published clinical studies evaluating the clinical efficacy and safety of lactulose compared with other laxatives or placebo. Adverse effects associated with lactulose are also reported. Information was retrieved by searching the MEDLINE and EMBASE databases for
Lise Lotte Gluud et al.
Metabolic brain disease, 28(2), 221-225 (2013-01-01)
Hepatic encephalopathy (HE) is a serious complication of acute and chronic liver disease associated with severe morbidity and mortality. We performed updated random effects meta-analyses to evaluate the evidence for non-absorbable disaccharides (lactulose and lactitol), rifaximin and branched chain amino
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service